How the menstrual cycle might alter ADHD symptoms in women taking stimulant medication

The menstrual cycle appears to modulate the severity of attention-deficit/hyperactivity disorder (ADHD) traits in women taking common stimulant medications. A new small study suggests that these traits peak in severity during menstruation and ease soon after, pointing toward a need for hormone-aware treatment plans. The research was published in the Journal of Attention Disorders.

ADHD is a neurodevelopmental condition characterized by distraction, impulsivity, and hyperactive behavior. Medical professionals historically viewed the condition as something that primarily affected young boys. That diagnostic gap is rapidly closing, and women now make up nearly half of the adult ADHD population in the United States. Women often present with different behavioral patterns than men, leaning toward severe inattention and internalizing behaviors rather than disruptive hyperactivity.

Despite facing daily impairments in their careers and social lives, women remain largely underrepresented in ADHD research. One distinct biological variable separating women from men is the constant fluctuation of ovarian hormones. During the follicular phase of the menstrual cycle, estrogen levels rise and peak near ovulation. The subsequent luteal phase features elevated estrogen and progesterone, which then drop rapidly shortly before menstruation begins.

Researchers suspect these hormones play a direct role in brain chemistry. Low estrogen levels are thought to decrease dopamine signaling in the brain. Because dopamine is the primary neurotransmitter involved in focus and attention, these natural hormonal drops could theoretically worsen ADHD symptoms.

Researchers Rebecca Zaritsky, Stephanie C. Reed, and Suzette M. Evans wanted to understand how these hormonal variations interact with ADHD treatments. Prior laboratory work demonstrated that amphetamines, the most commonly prescribed class of ADHD medications, can be less effective during the luteal phase of the cycle. Case reports from clinical settings also hinted that some women experience worsening moods and fading concentration right before their periods.

The research team designed a study to track these daily changes prospectively. The investigators recruited participants through online advertisements to monitor their daily experiences. They screened for individuals between the ages of 18 and 40 who experienced regular menstrual cycles lasting between 21 and 35 days.

To join the study, participants had to report an ADHD diagnosis and currently use amphetamine salts (commonly known by brand names like Adderall) for treatment on at least five days of the week. The team excluded anyone taking hormonal birth control, as well as individuals using other psychiatric medications. After exclusions and dropouts, the researchers ended up with a small study of 30 participants who completed the required long-term tracking.

Each individual filled out an initial survey detailing their medical history, baseline mood, and general impulsive behaviors. Following this baseline assessment, participants completed a daily online survey for 35 consecutive days. This extended timeline ensured the researchers could capture data from one full menstrual cycle for every participant.

The daily questionnaires asked participants to rate their current ADHD symptoms on a standardized four-point scale. They evaluated 18 distinct symptoms, splitting them equally between inattentive traits and hyperactive-impulsive traits. Participants also rated their daily mood variations on a six-point scale measuring 17 distinct emotional states, and reported their exact medication dosage for the day. Finally, they noted whether they were actively menstruating or spotting.

The researchers averaged the daily survey responses and grouped them into three specific biological windows. These windows included the first five days of menstruation, the mid-follicular phase shortly after bleeding ends, and the late luteal phase just before the next period begins. Participants reported their most severe ADHD symptoms during the active menstruation phase. In contrast, they experienced comparatively milder symptoms during the mid-follicular phase.

When researchers separated the specific types of ADHD traits, hyperactive and impulsive behaviors showed variation across the cycle phases, but after adjusting for multiple comparisons this amounted only to a trend rather than a statistically significant difference. Inattentive symptoms also fluctuated, but the differences were not statistically significant. Participants did not report any differences in how much their symptoms generally impaired their daily lives across the different phases.

Mood tracking revealed a correlation between negative emotions and ADHD symptoms. Participants reported elevated negative moods during both the late luteal and menstruation phases compared to the mid-follicular phase. The individuals who experienced the largest drops in mood during menstruation also reported the greatest increases in ADHD symptoms. This correlation held true for both inattentive and hyperactive traits.

Daily amphetamine doses remained remarkably steady across the entire cycle. Participants did not instinctively take more medication to compensate for feeling more distracted or hyperactive during their periods. The research team had hypothesized that some participants using flexible dosing regimens might attempt to counteract their worsening symptoms with higher doses. This lack of adjustment might reflect strict prescribing practices, as many doctors do not encourage patients to alter their daily stimulant intake based on their menstrual cycles.

This research relied entirely on self-reported surveys. The investigators did not measure hormone levels in a laboratory to perfectly confirm each biological phase, opting instead to estimate phases based on reported bleeding days. The small sample size also limited the statistical power of the analysis, meaning the results require verification in larger populations. Because participants taking other psychiatric medications were excluded, the results might not represent individuals managing ADHD alongside conditions such as mood disorders or premenstrual dysphoric disorder.

The study design carried a few distinct demographic and methodological limitations. The researchers did not explicitly gather information on gender identity, meaning the relationship between gender identity, hormone cycles, and ADHD remains untested in this specific context. The standardized survey tool used to track daily symptoms was also based on older diagnostic criteria. This older framework lacks recent diagnostic updates designed to capture how ADHD presents in adults.

The research team also looked at baseline mental health using standardized questionnaires for depression and anxiety. They found a trend suggesting that individuals with higher baseline depression and anxiety scores might experience slightly smaller shifts in ADHD symptoms across their cycles. However, having a higher overall symptom count on average consistently predicted a lower ADHD-related quality of life.

Future studies will need to incorporate direct hormone sampling to precisely map biological changes to behavioral shifts. Researchers might also explore how oral contraceptives or specific antidepressants impact this hormonal cycle in neurodivergent populations. Some clinics have already begun testing symptom-based dosing regimens, where patients take slightly more medication during the specific weeks when their natural hormones work against them. Tracking these targeted interventions could eventually help doctors provide highly individualized care for women navigating adult ADHD.

The study, “Changes in ADHD Symptoms and Mood Across the Menstrual Cycle in Females Treated With Stimulants: A Pilot Study,” was authored by Rebecca Zaritsky, Stephanie C. Reed, and Suzette M. Evans.